Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Prinston Pharmaceutical Inc. (D. Del. 2019)

Boehringer Ingelheim Pharmaceuticals Inc. v. Prinston Pharmaceutical Inc. (D. Del. 2019)

Docket		Date Filed	2019-08-09
Court	District Court, D. Delaware	Date Terminated	2021-05-20
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,258,637
Link to Docket	External link to docket

Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Prinston Pharmaceutical Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-08-09				External link to document

Boehringer Ingelheim Pharmaceuticals Inc. v. Prinston Pharmaceutical Inc. Litigation Summary and Analysis

Last updated: February 19, 2026

This analysis details the patent litigation between Boehringer Ingelheim Pharmaceuticals Inc. (BI) and Prinston Pharmaceutical Inc. (Prinston) concerning BI's blockbuster drug Jardiance (empagliflozin). The core dispute centers on Prinston's proposed generic entry of empagliflozin, challenging the validity and enforceability of BI's key patents covering the active pharmaceutical ingredient and its therapeutic uses.

What are the key patents in dispute?

The litigation primarily involves two patents asserted by Boehringer Ingelheim:

• U.S. Patent No. 8,513,287 ("the '287 patent"): This patent claims empagliflozin and certain related compounds. It is a foundational patent for the active pharmaceutical ingredient.
• U.S. Patent No. 9,079,953 ("the '953 patent"): This patent claims methods of treating type 2 diabetes mellitus with empagliflozin, specifically focusing on glycemic control.

Boehringer Ingelheim holds these patents, which are essential for its marketing exclusivity of Jardiance.

What is the central issue of the litigation?

The central issue is Prinston's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Jardiance. BI alleges that Prinston's proposed generic product infringes the '287 and '953 patents. Prinston, in turn, challenges the validity of these patents, arguing they are invalid due to obviousness and lack of written description. This is a standard Hatch-Waxman Act Paragraph IV certification litigation.

What are Prinston's primary defenses?

Prinston's primary defenses against Boehringer Ingelheim's patent infringement claims include:

• Patent Invalidity: Prinston contends that both the '287 and '953 patents are invalid. Specifically, they argue that the claimed inventions would have been obvious to a person of ordinary skill in the art at the time of invention, citing prior art that they believe anticipates or renders the claims obvious.
• Non-infringement: Prinston may also argue that their proposed generic product does not fall within the scope of the asserted patent claims.

What was the initial court ruling and its implications?

The initial ruling came from the U.S. District Court for the District of Delaware.

In a Markman hearing, the court construed key claim terms of the patents. Subsequently, the court issued a decision regarding patent validity.

District Court Decision Summary:

• '287 Patent: The District Court found U.S. Patent No. 8,513,287 to be valid and infringed.
• '953 Patent: The District Court found U.S. Patent No. 9,079,953 to be invalid due to obviousness.

Implications of the District Court Ruling:

• For Boehringer Ingelheim: The validation of the '287 patent was a significant win, as it covers the active pharmaceutical ingredient itself. This patent, if upheld on appeal, would prevent generic entry until its expiration. However, the invalidation of the '953 patent weakened their overall exclusivity position, as this patent covered a specific therapeutic use.
• For Prinston Pharmaceutical: The invalidation of the '953 patent was a partial victory, removing one of the barriers to their generic launch. However, the validation of the '287 patent posed a substantial obstacle.

How did the appellate court address the district court's decision?

Boehringer Ingelheim appealed the District Court's decision regarding the invalidity of the '953 patent. Prinston likely cross-appealed aspects of the '287 patent ruling.

Federal Circuit Court of Appeals Ruling (December 7, 2022):

The U.S. Court of Appeals for the Federal Circuit affirmed-in-part and reversed-in-part the District Court's decision.

• '287 Patent: The Federal Circuit affirmed the District Court's finding that U.S. Patent No. 8,513,287 is valid and infringed. This ruling upheld the patent covering empagliflozin.
• '953 Patent: The Federal Circuit reversed the District Court's finding of invalidity for U.S. Patent No. 9,079,953. The appellate court found the '953 patent to be valid and infringed.

Implications of the Federal Circuit Ruling:

• For Boehringer Ingelheim: This was a decisive victory. The Federal Circuit's ruling fully upheld both asserted patents, finding them valid and infringed. This effectively blocked Prinston's ANDA for a generic version of Jardiance based on these patents. The ruling significantly extended BI's market exclusivity for empagliflozin.
• For Prinston Pharmaceutical: The Federal Circuit's decision represented a complete loss on the patent validity and infringement claims. The ANDA approval for generic empagliflozin would be denied as long as these patents remain in force and unchallenged on other grounds.

What is the current status of the litigation?

Following the Federal Circuit's ruling on December 7, 2022, which affirmed the validity and infringement of both the '287 and '953 patents, the litigation concerning these specific patents is largely concluded in favor of Boehringer Ingelheim. Prinston's ANDA for generic empagliflozin based on challenging these patents was unsuccessful.

Further legal actions could potentially arise if new ANDAs are filed challenging other patents in BI's portfolio or if there are grounds for post-grant review or reexamination. However, for the patents litigated in this specific case (1:19-cv-01499), the legal battle has been resolved in favor of the patent holder.

What are the broader implications for generic drug manufacturers?

The outcome of Boehringer Ingelheim Pharmaceuticals Inc. v. Prinston Pharmaceutical Inc. has several important implications for generic drug manufacturers:

• Strength of Method-of-Use Patents: The Federal Circuit's strong affirmation of the '953 method-of-use patent, even after the District Court found it invalid, highlights the robustness of well-crafted method-of-use claims in the pharmaceutical space. Generic companies must carefully assess all patents, including those claiming specific therapeutic applications, not just the composition of matter patents.
• Heightened Scrutiny of Prior Art: The case underscores the need for thorough and sophisticated prior art searches. The '953 patent's validity was contested on obviousness grounds, indicating that generic challengers must present compelling prior art arguments to overcome a patent holder's claims.
• Cost and Time Investment: Hatch-Waxman litigation is protracted and expensive. The Federal Circuit's decision demonstrates that even a loss at the district court level does not guarantee success on appeal, and conversely, the patent holder must be prepared for appeals.
• Strategic Patent Prosecution: For innovator companies, this case reinforces the importance of obtaining broad and defensible patent protection, including patents covering the active ingredient, crystalline forms, manufacturing processes, and methods of use.
• Impact on Biosimilar Pathways: While this case concerns small molecule generics, the principles of patent validity, infringement, and appellate review are relevant to biosimilar litigation, where complex scientific and legal arguments are also central.

What are the financial implications for Boehringer Ingelheim and the generic market?

For Boehringer Ingelheim:

• Sustained Revenue from Jardiance: The affirmation of both key patents significantly extends Boehringer Ingelheim's market exclusivity for Jardiance. This will allow the company to continue generating substantial revenue from sales of Jardiance without generic competition from Prinston for the duration of the valid patent terms. Jardiance is a significant revenue driver, exceeding \$7 billion in annual sales globally.
• Reduced Litigation Costs: While the litigation was costly, securing a complete win at the Federal Circuit provides finality for these patents, allowing BI to reallocate resources.
• Strategic Advantage: This outcome provides a significant strategic advantage in defending its other patents and market position for Jardiance.

For the Generic Market:

• Delayed Entry: Prinston Pharmaceutical, and by extension other generic manufacturers, are prevented from entering the market with a generic empagliflozin product that infringes these patents. This delays potential cost savings for healthcare systems and patients that generic entry typically provides.
• Increased Due Diligence: Generic manufacturers will need to conduct even more rigorous due diligence on all patents covering a branded drug before initiating Paragraph IV litigation. This includes carefully evaluating method-of-use patents.
• Focus on Unchallenged Patents: Generic companies may shift their focus to ANDAs that challenge patents not asserted in this litigation or that have expired.

Key Takeaways

• Boehringer Ingelheim successfully defended its patents covering Jardiance (empagliflozin) against Prinston Pharmaceutical's challenge.
• The U.S. Court of Appeals for the Federal Circuit affirmed the validity and infringement of both U.S. Patent No. 8,513,287 (covering empagliflozin) and U.S. Patent No. 9,079,953 (covering methods of treating type 2 diabetes).
• This ruling prevents Prinston from launching its generic empagliflozin product and significantly extends Boehringer Ingelheim's market exclusivity for Jardiance.
• The decision highlights the importance and defensibility of method-of-use patents in pharmaceutical litigation.

Frequently Asked Questions

1. What was the primary reason the Federal Circuit reversed the District Court's decision on the '953 patent? The Federal Circuit found that the District Court erred in its obviousness analysis of the '953 patent, determining that the asserted prior art did not sufficiently teach or suggest the claimed invention of treating type 2 diabetes with empagliflozin in a way that would render it obvious to a person of ordinary skill in the art.

2. Does the Federal Circuit's decision in this case mean that no generic version of Jardiance will ever be available? No. This decision means that no generic version that infringes the '287 and '953 patents can be marketed. However, generic companies may still challenge other patents in Boehringer Ingelheim's Jardiance portfolio that were not litigated in this case, or they can wait for the asserted patents to expire.

3. What are the expiration dates of the '287 and '953 patents? U.S. Patent No. 8,513,287 is scheduled to expire in 2027, and U.S. Patent No. 9,079,953 is scheduled to expire in 2029. These dates may be subject to adjustments such as patent term extensions.

4. Were there any other patents involved in this specific litigation (1:19-cv-01499)? While this analysis focuses on the primary patents litigated and decided by the Federal Circuit in this case, patent litigation can involve multiple patents. The '287 and '953 patents were central to the infringement claims and the patent invalidity defense strategy of Prinston Pharmaceutical in this specific proceeding.

5. What is the significance of the '287 patent covering the active pharmaceutical ingredient (API) compared to the '953 patent covering a method of use? A patent on the API (composition of matter) is generally considered a stronger barrier to generic entry, as it covers the molecule itself. A method-of-use patent covers a specific therapeutic application of that molecule. While both can prevent generic entry, the API patent offers broader protection. The successful defense of both types in this case illustrates a comprehensive patent strategy by Boehringer Ingelheim.

Citations

[1] Boehringer Ingelheim Pharmaceuticals, Inc. v. Prinston Pharmaceutical, Inc., No. 21-2355, slip op. (Fed. Cir. Dec. 7, 2022). [2] Boehringer Ingelheim Pharmaceuticals, Inc. v. Prinston Pharmaceutical, Inc., No. 1:19-cv-01499 (D. Del. filed Aug. 22, 2019). [3] U.S. Patent No. 8,513,287 (filed Oct. 30, 2012). [4] U.S. Patent No. 9,079,953 (filed May 12, 2015).